Mercaptopurine (6-MP)

Catalog No.S1305

Mercaptopurine (6-MP) Chemical Structure

Molecular Weight(MW): 152.18

Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.

Size Price Stock Quantity  
In DMSO USD 100 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.
Targets
PRPP Amidotransferase [2]
In vitro

Mercaptopurine is widely used to treat malignancies, rheumatic diseases, dermatologic conditions, inflammatory bowel disease, and solid organ transplant rejection. [1] Mercaptopurine inhibits purine nucleotide synthesis and metabolism by inhibiting an enzyme called Phosphoribosyl pyrophosphate amidotransferase (PRPP Amidotransferase). PRPP Amidotransferase is the rate limiting enzyme of purine synthesis. It alters the synthesis and function of RNA and DNA . Mercaptopurine interferes with nucleotide interconversion and glycoprotein synthesis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 leukemia cells Mme1SpVv[3Srb36gZZN{[Xl? NUXXRmtJUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJI9vKG23bITp[JJ2\y2{ZYPpd5RidnRiTEGyNVAhdGW3a3XtbYEh[2WubIOsJGlEPTB;MD6wNlQh|ryP NFXVfG4yQTB4MUC3
MT4 cells MlX1VJJwdGmoZYLheIlwdiCjc4PhfS=> MkTLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPVESgZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNUDPxE1? NWK0S|Z3OTd{NUS2Olk>
human CCRF-CEM cells MX7Qdo9tcW[ncnH0bY9vKGG|c3H5 MorRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFQ2LGMWNGVSClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OSEQvF2= NEPTe|cyPzJ3NE[2PS=>
human CCRF-SB cells MmnQVJJwdGmoZYLheIlwdiCjc4PhfS=> NVnqfVU2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDR3JHNVOEIHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1zIN88US=> M4njXFE4OjV2Nk[5
human SK-MEL-28 cells MX7Qdo9tcW[ncnH0bY9vKGG|c3H5 MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV3FUE0zQCClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OTVizszN Mo\KNVczPTR4Nkm=
human MCF7 cells NGLIWI5Rem:uaX\ldoF1cW:wIHHzd4F6 NIfFU5lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVMh|ryP M33iXlE4OjV2Nk[5
human HepG2 cells NVS5TXprWHKxbHnm[ZJifGmxbjDhd5NigQ>? MorERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYDHNkBk\WyuczDifUBOXFRiYYPzZZktKEmFNUC9PEDPxE1? MnrGNVczPTR4Nkm=
human DU145 cells M2DUZXBzd2yrZnXyZZRqd25iYYPzZZk> NHG1NopCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0zKM7:TR?= MnTnNVczPTR4Nkm=
mouse J774.A1 cells M{DjWnBzd2yrZnXyZZRqd25iYYPzZZk> M4qyT|Mh\GG7cx?= MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEp5N{SuRVEh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IF3UWEBkd264ZYLzbY9vKGG|c3H5MEBKSzVyPUCuNFA{KM7:TR?= MmHiNVY3PDNyNEC=
HEK293 cells M4\4cnBzd2yrZnXyZZRqd25iYYPzZZk> MlPEN{Bl[Xm| M1ftTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTGVMOjl|IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiY3;ueoVze2mxbjDhd5NigSxiSVO1NF0xNjByNzFOwG0> M2HMSVE3PjR|MESw
mouse J774 cells NHPhbZFRem:uaX\ldoF1cW:wIHHzd4F6 M1[2XVczKGh? M{PLc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViSke3OEBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZiY3XscEBoem:5dHigZYZ1\XJiN{KgbJJ{KGK7IF3UWEBu\XSqb3SsJGlEPTB;MD6wNFMh|ryP M3[1RlExPzV5N{C4
human PBMC NVrhemU6TnWwY4Tpc44h[XO|YYm= MmXxOEBl[Xm| M2n3SWlvcGmkaYTpc44hd2ZiVDDj[YxtKG2rdH;n[Y4ucW6mdXPl[EBjdGG|dH;n[Y5me2m|IHnuJIh2dWGwIGDCUWMh[W[2ZYKgOEBl[Xm|LDDJR|UxRTBwMUS5OUDPxE1? NHvnUmEyQDR4N{CwOy=>
HeLa cells NUWwUXJzS3m2b4TvfIlkcXS7IHHzd4F6 M4LTTlQ5KGh? MnnkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BifCCuYXegdIhie2Vib3[g[5Jwf3SqIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:Oi57IN88US=> MXOxPVcyOTl6Nx?=
A549 cells M1GwWGN6fG:2b4jpZ4l1gSCjc4PhfS=> NH7McFc1QCCq NEX6fGREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGG2IHzh[{BxcGG|ZTDv[kBoem:5dHigZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD12NzFOwG0> MUOxPVcyOTl6Nx?=
MCF7 cells NEe1b5lEgXSxdH;4bYNqfHliYYPzZZk> MoPmOFghcA>? M1HmU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XRibHHnJJBp[XOnIH;mJIdzd3e2aDDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTFwNDFOwG0> NXG0XZZuOTl5MUG5PFc>
MT4 cells M3zSZmN6fG:2b4jpZ4l1gSCjc4PhfS=> MnzxPVYhcA>? M3\0eGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1VPCClZXzsd{Bqdm[nY4Tl[EB4cXSqIFjUUHYuOSCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwQVAvOSEQvF2= NI\N[VgzOTd2MUGzNC=>
CCRF-CEM cells M2i1dnBzd2yrZnXyZZRqd25iYYPzZZk> MXO5OkBp MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOFUl[tR2VOKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGNEPTB;MTFOwG0> NELIT5IzOTd2MUGzNC=>
WIL2-NS cells M1XVfHBzd2yrZnXyZZRqd25iYYPzZZk> M3vDZlk3KGh? M3\DfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV1nMNk1PWyClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBESzVyPUOg{txO MVGyNVc1OTF|MB?=
CCRF-SB cells Ml[wVJJwdGmoZYLheIlwdiCjc4PhfS=> MXS5OkBp Mkn1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFQ2LGMXNDKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGNEPTB;MT6xJO69VQ>? MWqyNVc1OTF|MB?=
human DU145 cells MXzQdo9tcW[ncnH0bY9vKGG|c3H5 MV25OkBp NVmyPGl4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBESzVyPUKg{txO M3PsflIyPzRzMUOw
human HepG2 cells NYLzN4t4WHKxbHnm[ZJifGmxbjDhd5NigQ>? Ml71PVYhcA>? MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:QCEQvF2= M3m5OlIyPzRzMUOw
MCF7 cells MYTQdo9tcW[ncnH0bY9vKGG|c3H5 MV[5OkBp MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NF0{NjJizszN NVv0U29nOjF5NEGxN|A>
SK-MEL-28 cells M{\6fnBzd2yrZnXyZZRqd25iYYPzZZk> MVq5OkBp M134OmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEOFNUC9NVUh|ryP MnTONlE4PDFzM{C=
MCF7 cells MoSxR5l1d3SxeHnjbZR6KGG|c3H5 M{LNZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMtKEmFNUC9Nk44QSEQvF2= MortNlM1OTF7MUW=
mouse S49 cells MYHDfZRwfG:6aXPpeJkh[XO|YYm= NXvm[4h7PzJiaB?= MY\DfZRwfG:6aXPpeJkh[WejaX7zeEB4cWymIIT5dIUhdW:3c3WgV|Q6KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUB1enmyYX6gZox2\SCneHPseZNqd25iYYPzZZktKEWFNUC9PEDPxE1? M37aV|IzOTZ3OB?=
Colo-357 cells MoTvR5l1d3SxeHnjbZR6KGG|c3H5 NV6xeJE5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS2:ubz2zOVch[2WubIOgZpkh[3K7c4ThcEB3cW:uZYSgd5RicW6rbnesJGlEPTB;Nj6xNkDPxE1? MWqyNFk{ODF{Mx?=
Aspc-1 cells NVqyeo4{S3m2b4TvfIlkcXS7IHHzd4F6 NUnFfWxnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSXOyYz2xJINmdGy|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pLDDJR|UxRTJwNEWg{txO MmrMNlA6OzBzMkO=
A549 cells NXLMb4NES3m2b4TvfIlkcXS7IHHzd4F6 M{\TcVQ5KGh? M2fQOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20O{DPxE1? MofPNlI4ODVyMEG=
MCF7 cells M13CVmN6fG:2b4jpZ4l1gSCjc4PhfS=> MX[0PEBp MnLiR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuOEDPxE1? NGXY[lIzOjdyNUCwNS=>
Patu-02 cells NVew[mtWS3m2b4TvfIlkcXS7IHHzd4F6 MkTBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVIF1fS1yMjDj[YxteyCkeTDjdpl{fGGuII\pc4xmfCC|dHHpcolv\yxiSVO1NF06NjZ7IN88US=> MkTQNlA6OzBzMkO=
Patu-T cells NWPKSXloS3m2b4TvfIlkcXS7IHHzd4F6 MojKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVIF1fS2WIHPlcIx{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNCCLQ{WwQVQvODlizszN MV[yNFk{ODF{Mx?=
Patu-S cells MWLDfZRwfG:6aXPpeJkh[XO|YYm= MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQZZR2NVNiY3XscJMh[nliY4L5d5RidCC4aX;s[ZQhe3SjaX7pcoctKEmFNUC9NVEvODdizszN MUSyNFk{ODF{Mx?=
T3M4 cells MkDQR5l1d3SxeHnjbZR6KGG|c3H5 MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUN201KGOnbHzzJIJ6KGO{eYP0ZYwhfmmxbHX0JJN1[WmwaX7nMEBKSzVyPUKuOlMh|ryP NIfzTZAzODl|MEGyNy=>
human PANC1 cells MUDDfZRwfG:6aXPpeJkh[XO|YYm= M1Xlc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBCVkNzIHPlcIx{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNCCLQ{WwQVYvOzlizszN M3m2PVIxQTNyMUKz
human DAN-G cells MlPGR5l1d3SxeHnjbZR6KGG|c3H5 MonUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSGFPNUdiY3XscJMh[nliY4L5d5RidCC4aX;s[ZQhe3SjaX7pcoctKEmFNUC9OE4xPiEQvF2= NXOzVpB[OjB7M{CxNlM>
HeLa cells M1fVTmN6fG:2b4jpZ4l1gSCjc4PhfS=> NWn6[JlbPDhiaB?= Mn3UR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUKuPUDPxE1? Ml[xNlI4ODVyMEG=
WEHI164 cells MXTQdo9tcW[ncnH0bY9vKGG|c3H5 NFrpSWs{KGSjeYO= NHeyZ3JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIGfFTGkyPjRiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCClb372[ZJ{cW:wIHHzd4F6NCCLQ{WwQVAvODF3IN88US=> NIe2OIsyPjZ2M{C0NC=>
WIL-2NS cells MXPQdo9tcW[ncnH0bY9vKGG|c3H5 Mn;aRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCZSVytNm5UKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0{KM7:TR?= NILZOGMyPzJ3NE[2PS=>
WEHI164 cells M3fnfnBzd2yrZnXyZZRqd25iYYPzZZk> NInzbGo4OiCq MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKFeHSFmxOlQh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIHPlcIwh\3Kxd4ToJIFnfGW{IEeyJIhzeyCkeTDNWHQhdWW2aH;kMEBKSzVyPUCuNFE4KM7:TR?= MWqxNFc2PzdyOB?=

... Click to View More Cell Line Experimental Data

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (197.13 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 152.18
Formula

C5H4N4S

CAS No. 50-44-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00514982 Withdrawn Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymphocytes|Drug Evaluation National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) August 7, 2007 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT02578511 Not yet recruiting Acute Lymphoblastic Leukemia in Complete Remission|Lymphoblastic Lymphoma in Complete Remission|Mixed Phenotype Acute Leukemia in Complete Remission Ehab L Atallah|Medical College of Wisconsin January 2017 Phase 1
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02828358 Not yet recruiting Acute Leukemia of Ambiguous Lineage|Childhood B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia National Cancer Institute (NCI) December 2016 --
NCT02877303 Recruiting Leukemia|Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center|Amgen November 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Mercaptopurine (6-MP) | Mercaptopurine (6-MP) supplier | purchase Mercaptopurine (6-MP) | Mercaptopurine (6-MP) cost | Mercaptopurine (6-MP) manufacturer | order Mercaptopurine (6-MP) | Mercaptopurine (6-MP) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID